(UroToday.com) At the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) session on optimizing personalized management of non-muscle invasive bladder cancer included a debate regarding the optimal therapy for BCG-unresponsive disease among patients that are not cystectomy candidates. Dr. Arjun Balar from NYU in New York made the argument for systemic therapy as the optimal treatment.